Bristol-Meyers Squibb Company BMY reported stronger-than-expected results for the fourth quarter, but the company issued a downbeat FY15 outlook.
The New York-based company reported a quarterly profit of $13 million, or $0.01 per share, compared to $726 million, or $0.44 per share, in the year-ago period. Its adjusted earnings came in at $0.46 per share.
Its revenue fell 4% to $4.26 billion. However, analysts were expecting earnings of $0.41 per share on revenue of $4.04 billion.
U.S. revenues slipped 8% to $2.1 billion in the period. Gross margin widened to 77.3% from 71.3%.
Marketing, selling and administrative expenses rose 8% to $1.2 billion, while research and development expenses gained 24% to $1.2 billion in the quarter.
"We had an excellent fourth quarter to close a strong year financially and operationally, and made significant progress in our I-O pipeline with the approval of Opdivo in the U.S. for patients with advanced melanoma,” said Lamberto Andreotti, chief executive officer, Bristol-Myers Squibb.
For the full-year, Bristol-Meyers Squibb projects adjusted earnings of $1.55 to $1.70 on revenue of $14.4 billion to $15 billion. Analysts expected earnings of $1.70 per share on revenue of $15.64 billion.
Bristol-Meyers Squibb shares declined 0.90% to $61.90 in pre-market trading.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in